Insider Transactions in Q1 2021 at Royalty Pharma PLC (RPRX)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2021
|
Henry A Fernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
816
+7.89%
|
$36,720
$45.9 P/Share
|
|
Mar 31
2021
|
Bonnie L Bassler Director |
BUY
Grant, award, or other acquisition
|
Direct |
816
+5.1%
|
$36,720
$45.9 P/Share
|
|
Mar 22
2021
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
54,729
-9.75%
|
$2,517,534
$46.57 P/Share
|
|
Mar 22
2021
|
James F. Reddoch EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
43,927
-14.64%
|
$2,020,642
$46.32 P/Share
|
|
Mar 03
2021
|
Terrance P. Coyne EVP & CFO |
SELL
Open market or private sale
|
Indirect |
100,000
-9.3%
|
$4,500,000
$45.37 P/Share
|
|
Mar 02
2021
|
Terrance P. Coyne EVP & CFO |
SELL
Open market or private sale
|
Indirect |
100,000
-12.7%
|
$4,700,000
$47.39 P/Share
|
|
Mar 02
2021
|
James F. Reddoch EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
100,000
-12.64%
|
$4,700,000
$47.37 P/Share
|
|
Mar 02
2021
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
125,000
-12.76%
|
$5,875,000
$47.37 P/Share
|
|
Feb 25
2021
|
Henry A Fernandez Director |
BUY
Open market or private purchase
|
Indirect |
25,700
+50.0%
|
$1,182,200
$46.83 P/Share
|